Jerome O Cantor, 75258 82Nd St, Brooklyn, NY 11209

6391861, May 21, 2002

May 14, 1998

09/079209

Jerome O. Cantor - Bronx NY

The Trustees of Columbia University in the City of New York - New York NY

A61K 31715

514 54, 514 59, 514 21, 514 2, 424422, 424423, 424424, 424425, 530350, 530356, 530857, 604289, 604290, 604304, 604306, 604307

The subject invention is directed to the prevention of elastic fiber injury by administering HA or any other polysaccharide or carbohydrate moiety that binds to and coats elastic fibers, thereby preventing enzymes, oxidants, or other injurious agents from contacting and damaging these fibers. The method may be used to prevent elastic fiber damage which occurs to the skin and blood vessels as a consequence of aging, to the uterus during pregnancy, and in diseases such as pulmonary emphysema, aortic aneurysm, and joint disease. The treatment is intended for humans and a variety of other mammals. The polysaccharide or carbohydrate moiety may be administered orally, cutaneously, subcutaneously, intravenously, intratracheally, or by any other route deemed efficacious. It may be administered alone or in combination with another polysaccharide or carbohydrate moiety, with or without a carrier such as saline solution, DMSO, alcohol or water. It may be naturally occurring, chemically modified, or artificially synthesized.

6776989, Aug 17, 2004

Apr 5, 2001

09/826731

Jerome Owen Cantor - Bayside NY, 11360
Bronislava Shteyngart - Brooklyn NY, 11209

A61K 3847

424 9461, 435206, 424 43

The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme. Respiratory disorders include emphysema, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of lysozyme may be performed by aerosol, which can be generated by a nebulizer or by instillation. The lysozyme may be administered alone or with a carrier such as saline solution, DMSO, and alcohol, or water. It may also be used as a vehicle for the intratracheal administration of drugs or other agents to the lung. The lysozyme may be isolated from a natural source, such as eggs, or synthesized by a bioprocess, such as fermentation. The effective daily amount of lysozyme is from about 10 g/kg to about 1 mg/kg of body weight.

7026287, Apr 11, 2006

May 12, 2003

10/435549

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

A61K 38/16

514 8, 514 2, 5303875, 530395, 424725

The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.

7166437, Jan 23, 2007

Sep 24, 2002

10/253756

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

G01N 33/53
G01N 33/537
G01N 30/90
G01N 24/00
G01N 33/557
G01N 33/543
C12N 9/00

435 71, 435 792, 435183, 436162, 436173, 436517, 436518

The subject invention is directed to the measurement of elastic fiber breakdown products in human sputum obtained from patients with emphysema and other lung diseases. Measurement of elastic fiber breakdown products may be used to monitor the progression of lung disease or to assess the efficacy of a treatment for lung disease. Such breakdown products are associated with lung injury resulting from degradation of lung elastic fibers. This process may occur in emphysema and other inflammatory disease of the lung where excess amounts of elastase are secreted by inflammatory cells. The methods for measuring elastin breakdown products in certain tissue fluids (i. e. blood, urine, bronchoalveolar lavage fluid) are well known to the art but have not been previously applied to sputum samples. The use of sputum has several advantages over other fluids, including greater specificity and ease of procurement.

7364888, Apr 29, 2008

Jul 7, 2005

11/175332

Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US

C12N 9/00

435183

The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.

2002008, Jul 4, 2002

May 23, 2001

09/863849

Jerome Cantor - Brooklyn NY, US
Jing-wen Kuo - Wakefield MA, US
Paul Mihalko - Fremont CA, US
Dan Sachs - Boston MA, US
Gerard Turino - New York NY, US

A61K031/737
A61K031/728
A61K031/727
A61K009/00
A61L009/04

514/054000, 514/056000, 424/043000

The present invention relates generally to the field of respiratory therapeutics, and in particular to the treatment of disorders of the lung matrix caused by damage to the elastic fibers of the lung matrix. More specifically, methods and materials are disclosed for the delivery to the lungs of polysaccharides, derivatives thereof and/or drug conjugates, used in the treatment and/or prevention of pulmonary disorders.

2009001, Jan 8, 2009

Jul 5, 2007

11/824860

Jerome Cantor - Brooklyn NY, US
Tapan Bhavsar - Queens NY, US
Sandra Reznik - Larchmont NY, US

A61K 31/70
A61P 11/00

514 25

The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of an agent that suppresses the activity of endothelin. Such agents may take the form of: 1) an endothelin-converting enzyme (ECE) inhibitor such as phosphoramidon, or 2) an endothelin receptor antagonist such as bosentan, tezosentan, sitaxsentan, atrasentan, darusentan, clazosentan, or BQ-123. Respiratory disorders include emphysema, asthma, bronchitis, bronchiectasis, pneumonia, adult respiratory distress syndrome, neonatal respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, persistent pulmonary hypertension of the newborn, and neoplasia. The treatment is intended for a variety of mammals, such as premature neonates to adult humans.

2009014, Jun 4, 2009

Sep 10, 2008

12/283215

Ralph Anthony Stephani - Mamaroneck NY, US
Hardik Jitendra Patel - Flushing NY, US
Sandra Eve Reznik - Larchmont NY, US
Jerome Owen Cantor - Brooklyn NY, US

A61K 31/4709
A61P 9/00
A61P 11/00
A61P 1/00
A61P 7/00

514312

The invention discloses the composition and preparation of various 1,3,6-trisubstituted-2-carboxy-quinol-4-ones of the formula 1 where R is H, alkyl, haloalkyl or hydroxyalkyl, R′ is alkyl, nitro, halogen or NR′″ where R′″ is alkyl or cycloalkyl, and R″ is H or alkyl. The composition of the invented compounds as methods of antagonizing the action of endothelin-1 to treat cardiovascular, pulmonary diseases and obstetric disorders and preterm labor and preeclampsia in mammals is disclosed.